Neogenomics (NEO) Cash & Equivalents (2010 - 2026)

Neogenomics (NEO) has 17 years of Cash & Equivalents data on file, last reported at $145.5 million in Q2 2026.

• Quarterly Cash & Equivalents fell 5.94% year-over-year to $145.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $145.5 million (down 5.94% YoY) and the FY2025 annual result came in at $159.6 million, down 56.51% from the prior year.
• Cash & Equivalents steadied at $145.5 million in Q2 2026, from $146.1 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $367.0 million in Q4 2024 to a low of $145.5 million in Q2 2026.
• A 5-year average of $270.3 million and a median of $286.4 million in 2022 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2023 — Cash & Equivalents surged 30.13% — and 2026, when it plunged 57.79%.
• Tracing NEO's Cash & Equivalents over 5 years: stood at $263.2 million in 2022, then soared by 30.13% to $342.5 million in 2023, then increased by 7.16% to $367.0 million in 2024, then tumbled by 56.51% to $159.6 million in 2025, then slipped by 8.82% to $145.5 million in 2026.
• The last three Cash & Equivalents figures came in at $145.5 million (Q2 2026), $146.1 million (Q1 2026), and $159.6 million (Q4 2025), per Business Quant data.